Omalizumab

Abstract

Angioedema: case report In a large, two-year multi-centre observational study, involving 195 patients treated for chronic spontaneous urticaria, one patient [age and sex not stated] was described, who developed angioedema (involving swelling of the face, lips, tongue and throat) during treatment with SC omalizumab 300mg every 4 weeks for 24 weeks (first course). Therefore, the patient discontinued omalizumab after the first course [time to reaction onset and outcome not stated].